Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The business and product range of Ipca and that of Unichem complements each others business and product range
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Enabling wireless monitoring In ambulances and homes
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.
To enable company to be future-ready by tapping potential in CDMO space
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
Subscribe To Our Newsletter & Stay Updated